- Home
- OPEN vs PCVX Comparison
OPEN vs PCVX Comparison
Compare OPEN & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPEN
- PCVX
- Stock Information
- Founded
- OPEN 2014
- PCVX 2013
- Country
- OPEN United States
- PCVX United States
- Employees
- OPEN N/A
- PCVX N/A
- Industry
- OPEN Real Estate
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- OPEN Finance
- PCVX Health Care
- Exchange
- OPEN Nasdaq
- PCVX Nasdaq
- Market Cap
- OPEN 4.9B
- PCVX 4.0B
- IPO Year
- OPEN N/A
- PCVX 2020
- Fundamental
- Price
- OPEN $7.16
- PCVX $40.80
- Analyst Decision
- OPEN Sell
- PCVX Strong Buy
- Analyst Count
- OPEN 4
- PCVX 8
- Target Price
- OPEN $1.45
- PCVX $114.17
- AVG Volume (30 Days)
- OPEN 109.0M
- PCVX 1.5M
- Earning Date
- OPEN 11-06-2025
- PCVX 11-05-2025
- Dividend Yield
- OPEN N/A
- PCVX N/A
- EPS Growth
- OPEN N/A
- PCVX N/A
- EPS
- OPEN N/A
- PCVX N/A
- Revenue
- OPEN $5,181,000,000.00
- PCVX N/A
- Revenue This Year
- OPEN N/A
- PCVX N/A
- Revenue Next Year
- OPEN N/A
- PCVX N/A
- P/E Ratio
- OPEN N/A
- PCVX N/A
- Revenue Growth
- OPEN 14.07
- PCVX N/A
- 52 Week Low
- OPEN $0.51
- PCVX $27.66
- 52 Week High
- OPEN $10.87
- PCVX $116.00
- Technical
- Relative Strength Index (RSI)
- OPEN 47.28
- PCVX 47.89
- Support Level
- OPEN $6.86
- PCVX $43.12
- Resistance Level
- OPEN $8.02
- PCVX $45.90
- Average True Range (ATR)
- OPEN 0.58
- PCVX 1.86
- MACD
- OPEN -0.10
- PCVX -0.59
- Stochastic Oscillator
- OPEN 39.87
- PCVX 15.01
About OPEN Opendoor Technologies Inc
Opendoor Technologies Inc is an end-to-end real estate platform enabling customers to sell and buy a home online. Its product offerings include Sell to Opendoor, its core product where sellers sell their homes directly to the company, and it resells those homes to buyers; List with Opendoor, for customers to list their homes with a partner agent; and Opendoor Marketplace, a capital light marketplace offering that connects home sellers with both institutional and retail buyers. In addition to these products, the company also offers its customers integrated title insurance and escrow services through its subsidiaries. A vast majority of the company's revenue is generated by its core product offering, where it acquires homes directly from sellers and resells those homes to buyers.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.